Table 1 Baseline disease characteristics (Calabresi et al. [5])
Characteristic | Placebo | Peginterferon beta-1a | |
|---|---|---|---|
Every 4 weeks | Every 2 weeks | ||
All patients, n | 500 | 500 | 512 |
Relapses in the 12 months prior to enrolment, mean (SD) | 1.6 (0.67) | 1.5 (0.62) | 1.6 (0.67) |
Baseline EDSS score, mean (SD) | 2.44 (1.18) | 2.48 (1.24) | 2.47 (1.26) |
T2 lesions at baseline | |||
Patients with available data, n | 497 | 499 | 511 |
Mean number of lesions (SD) | 50.6 (35.7) | 51.4 (36.0) | 48.7 (36.8) |
Patients with no T2 lesions at baseline, n (%) | 0 | 3 (<1) | 4 (<1) |
Gd + lesions at baseline | |||
Patients with available data, n | 497 | 498 | 510 |
Mean number of lesions (SD) | 1.6 (3.8) | 1.8 (5.4) | 1.2 (3.4) |
Patients with no Gd + lesions at baseline, n (%) | 296 (59.6) | 297 (59.6) | 334 (65.5) |